Ensign Peak Advisors
NVO

Ensign Peak Advisors’s Novo Nordisk NVO Stock Holding History

Ensign Peak Advisors’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-400,384
Closed -$14.7M – 1741
2026
Q1 		$14.7M Buy
+400,384
New +$19M 0.03% 345
2025
Q1 		– Sell
-469,351
Closed -$40.4M – 1712
2024
Q4 		$40.4M Sell
469,351
-314,386
-40% -$34M 0.07% 213
2024
Q3 		$93.3M Sell
783,737
-1,814
-0.2% -$242K 0.16% 113
2024
Q2 		$112M Buy
785,551
+192,541
+32% +$25.5M 0.2% 96
2024
Q1 		$76.1M Buy
+593,010
New +$70.6M 0.14% 147

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Ensign Peak Advisors's NVO Position: Q2 2026 in Review

Ensign Peak Advisors sold out of Novo Nordisk (NVO) in Q2 2026, closing a stake of 400,384 shares — an estimated $14.7M sold.

Ensign Peak Advisors first reported a position in NVO in Q1 2024 and held it in 5 quarters. The position peaked at $112M in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Ensign Peak Advisors reported no remaining Novo Nordisk position as of Q2 2026 after selling out during the quarter.
  • Ensign Peak Advisors sold 400,384 Novo Nordisk shares in Q2 2026, an estimated $14.7M.
  • Ensign Peak Advisors first reported a position in Novo Nordisk in Q1 2024 and held it in 5 quarters.
  • Ensign Peak Advisors's Novo Nordisk position peaked at $112M in Q2 2024.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.